A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
Public ClinicalTrials.gov record NCT05055258. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
Study identification
- NCT ID
- NCT05055258
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2021 (Actual)
- Primary completion
- Oct 27, 2022 (Actual)
- Completion
- Oct 27, 2022 (Actual)
- Last update posted
- May 6, 2026
2021 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| KalVista Investigative Site | Birmingham | Alabama | 35294 | — |
| KalVista Investigative Site | Scottsdale | Arizona | 85251 | — |
| KalVista Investigative Site | La Jolla | California | 92093 | — |
| KalVista Investigative Site | Santa Monica | California | 90404 | — |
| KalVista Investigative Site | Centennial | Colorado | 80112 | — |
| KalVista Investigative Site | Tampa | Florida | 33620 | — |
| KalVista Investigative Site | Chevy Chase | Maryland | 20815 | — |
| KalVista Investigative Site | Boston | Massachusetts | 02114 | — |
| KalVista Investigative Site | St Louis | Missouri | 63110 | — |
| KalVista Investigative Site | Cincinnati | Ohio | 45231 | — |
| KalVista Investigative Site | Hershey | Pennsylvania | 17033 | — |
| KalVista Investigative Site | Dallas | Texas | 75390 | — |
| KalVista Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05055258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05055258 live on ClinicalTrials.gov.